**Supplementary Table 5** Comparison of the aMAP-CT, model with aMAP and liver signatures (aMAP+liver), model with aMAP and spleen signatures (aMAP+spleen), and aMAP model in HCC risk stratification. Abbreviations: HCC, hepatocellular carcinoma.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Models** | **High-risk,**  **n (%)** |  | **HR**  **(95% CI)** |  | **3-year cumulative incidence of HCC** | |  | **1-year cumulative incidence of HCC** | |
|  |  | **High-risk group** | **Low-risk group** |  | **High-risk group** | **Low-risk group** |
| aMAP-CT | 183  (7.6%) |  | 12.3  (5.8-26.0) |  | 26.3% | 1.7% |  | 13.3% | 0.7% |
| aMAP+liver | 271  (11.2%) |  | 4.0  (2.2-7.1) |  | 12.8% | 2.4% |  | 6.3% | 1.1% |
| **aMAP+spleen** | **163**  **(6.8%)** |  | **3.9**  **(1.7-8.7)** |  | **12.2%** | **3.0%** |  | **7.5%** | **1.3%** |
| aMAP | 1014  (42.1%) |  | 3.1  (2.2-4.5) |  | 5.9% | 1.9% |  | 2.9% | 0.8% |